Tradestie Institutional Equity Comparison Engine

SGP vs DNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SGP Overall Edge

SGP Captures Institutional Edge (2โ€“1 Pillars ยท 2โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SGP (SGP) driven by superior Momentum & Technical, Options & Structure while DNA counters with relative strength in Growth & Margin. Fundamentally, SGP trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus DNA at N/M Forward P/E and -202.5% operating margin (-5.7% YoY). In options structure, SGP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DNA sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SGP N/M vs DNA N/M Fwd P/E
Growth & Margin Winner DNA
Op Margin N/A vs -202.5% ยท YoY N/A vs -5.7%
Momentum & Technical Winner SGP
1Y +22.1% vs +6.2% ยท 52W Pos 66% vs 24%
Options & Structure Winner SGP
UNCLASSIFIED (N/A IV) vs BREAKDOWN (34th %ile IV)
SGP US Equity
SGP
Institutional Equity
$32.24
-1.95% 1D
Market Cap N/A
1M Return +34.33%
1Y Return +22.12%
Forward P/E N/M
Unified AI Score
39.3 / 100 SELL
Tech 15.0 Fund 45.0 Flow 50.0 Mom 60.0
DNA NYSE
Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Disgnostic Substances)
$8.50
-11.55% 1D
Market Cap $623.0M
1M Return -17.23%
1Y Return +6.25%
Forward P/E N/M
Unified AI Score
57.4 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SGP +22.12% DNA +6.25% Spread: +37.96 pp (SGP Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SGP TTM Op. Margin: N/A DNA TTM Op. Margin: -202.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGP vs DNA. Trailing 12-month operating profitability (SGP N/A vs DNA -202.5%) and valuation multiples (SGP N/M vs DNA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SGP (2) vs DNA (6)
Institutional Metric SGP DNA Criterion Row Winner
Market Capitalization Scale N/A $623.0M Larger Scale DNA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A -5.7% Higher Growth DNA
Operating Margin (TTM) Profitability N/A -202.5% Higher Margin DNA
Net Profit Margin Profitability N/A -192.0% Higher Margin DNA
Return on Equity (ROE) Capital Efficiency N/A -58.2% Higher ROE DNA
52-Week Range Position Momentum 66% ($17โ€“$40) 24% ($5โ€“$18) Stronger Trend SGP
Beta / 30D Volatility Risk Regime 1.38ฮฒ ยท 70% Vol 3.14ฮฒ ยท 152% Vol Lower Realized Risk SGP
Unified Institutional Score Composite Signal 39.3 / 100 (SELL) 57.4 / 100 (HOLD) Higher Composite DNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SGP vs DNA Buy Guide
SGP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live SGP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DNA BREAKDOWN
30d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 34th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live DNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SGP nor DNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.